Comparison of Metabolic and Anatomic Response to Chemotherapy Based on PERCIST and RECIST in Patients with Advanced Stage Non-small Cell Lung Cancer

Ordu, Cetin; Selcuk, Nalan A.; Akosman, Cengiz; Eren, Orhan Onder; Altunok, Elif C.; Toklu, Turkay; Oyan, Basak

추천

검색

자료유형: 학술저널

저자정보: Ordu, Cetin (Department of Internal Medicine, Faculty of Medicine, Bilim University) Selcuk, Nalan A. (Department of Nuclear Medicine, Yeditepe University Hospital) Akosman, Cengiz (Medical Oncology Section, Department of Internal Medicine, Yeditepe University Hospital) Eren, Orhan Onder (Medical Oncology Section, Department of Internal Medicine, Yeditepe University Hospital) Altunok, Elif C. (Department of Biostatistics, Yeditepe University Hospital) Toklu, Turkay (Department of Nuclear Medicine, Yeditepe University Hospital) Oyan, Basak (Medical Oncology Section, Department of Internal Medicine, Yeditepe University Hospital)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제16권 제1호

발행연도: 2015.1

수록면: 321 - 326 (6page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: The aim of this study was to explore the prognostic role of metabolic response to chemotherapy, determined by FDG-PET, in patients with metastatic non-small-cell lung cancer (NSCLC). Materials and Methods: Thirty patients with metastatic NSCLC were analyzed for prognostic factors related to overall survival (OS) and progression free survival (PFS). Disease evaluation was conducted with FDG-PET/CT and contrast-enhanced CT prior to and at the end of first-line chemotherapy. Response evaluation of 19 of 30 patients was also performed after 2-3 cycles of chemotherapy. Morphological and metabolic responses were assessed according to RECIST and PERCIST, respectively. Results: The median OS and PFS were 11 months and 6.2 months, respectively. At the end of first-line chemotherapy, 10 patients achieved metabolic and anatomic responses. Of the 19 patients who had an interim response analysis after 2-3 cycles of chemotherapy, 3 achieved an anatomic response, while 9 achieved a metabolic response. In univariate analyses, favorable prognostic factors for OS were number of cycles of first-line chemotherapy, and achieving a response to chemotherapy at completion of therapy according to the PERCIST and RECIST. The OS of patients with a metabolic response after 2-3 cycles of chemotherapy was also significantly extended. Anatomic response at interim analysis did not predict OS, probably due to few patients with anatomic response. In multivariate analyses, metabolic response after completion of therapy was an independent prognostic factor for OS. Conclusions: Metabolic response is at least as effective as anatomic response in predicting survival. Metabolic response may be an earlier predictive factor for treatment response and OS in NSCLC patients.

#Advanced stage #non-small cell lung cancer #PERCIST #RECIST #FDG-PET #survival

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!